Eli Lilly’s ongoing non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, originally signed in October 2024 and extended through October 2026, anchors trader sentiment near even odds. This setup allows Lilly to test the ultrasonic spray-drying technology on peptide candidates like GLP-1 agonists without committing to commercial rights, while recent clarifications confirm the pact remains active despite Lilly’s separate FluidCrystal licensing and push toward oral orforglipron formulations. Key swing factors include upcoming data readouts from the joint research committee, potential technology-transfer milestones tied to Lilly’s $500 million South Korea clinical hub, and any binding commercial licensing terms before the October 7 deadline.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트신규
신규
2026.10.07
신규
신규
2026.10.07
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, originally signed in October 2024 and extended through October 2026, anchors trader sentiment near even odds. This setup allows Lilly to test the ultrasonic spray-drying technology on peptide candidates like GLP-1 agonists without committing to commercial rights, while recent clarifications confirm the pact remains active despite Lilly’s separate FluidCrystal licensing and push toward oral orforglipron formulations. Key swing factors include upcoming data readouts from the joint research committee, potential technology-transfer milestones tied to Lilly’s $500 million South Korea clinical hub, and any binding commercial licensing terms before the October 7 deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
마켓 개설일: May 5, 2026, 8:02 PM ET
거래량
$8,224종료일
2026.10.07마켓 개설일
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, originally signed in October 2024 and extended through October 2026, anchors trader sentiment near even odds. This setup allows Lilly to test the ultrasonic spray-drying technology on peptide candidates like GLP-1 agonists without committing to commercial rights, while recent clarifications confirm the pact remains active despite Lilly’s separate FluidCrystal licensing and push toward oral orforglipron formulations. Key swing factors include upcoming data readouts from the joint research committee, potential technology-transfer milestones tied to Lilly’s $500 million South Korea clinical hub, and any binding commercial licensing terms before the October 7 deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
거래량
$8,224종료일
2026.10.07마켓 개설일
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing non-exclusive evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, originally signed in October 2024 and extended through October 2026, anchors trader sentiment near even odds. This setup allows Lilly to test the ultrasonic spray-drying technology on peptide candidates like GLP-1 agonists without committing to commercial rights, while recent clarifications confirm the pact remains active despite Lilly’s separate FluidCrystal licensing and push toward oral orforglipron formulations. Key swing factors include upcoming data readouts from the joint research committee, potential technology-transfer milestones tied to Lilly’s $500 million South Korea clinical hub, and any binding commercial licensing terms before the October 7 deadline.
Polymarket 데이터를 참조하는 실험적 AI 생성 요약입니다. 이것은 거래 조언이 아니며 이 마켓의 정산에 영향을 미치지 않습니다. · 업데이트
외부 링크에 주의하세요.
외부 링크에 주의하세요.
자주 묻는 질문